Stacie L. Stapleton
Expertise in
11
conditions

Dr. Stacie L. Stapleton

Pediatrics | Palliative Medicine | Pediatric Hematology Oncology
Johns Hopkins Medicine
Johns Hopkins All Children's Outpatient Care, St. Petersburg
Saint Petersburg, FL 

Expertise in
11
conditions
Johns Hopkins Medicine
Johns Hopkins All Children's Outpatient Care, St. Petersburg
Saint Petersburg, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Stapleton is the division chief of oncology and director of pediatric neuro-oncology at Johns Hopkins All Children’s Hospital. Dr. Stapleton joined the hospital in 2007. She has formal training in pediatric neuro-oncology. She received the Armstrong Award for Quality and Patient Safety for Johns Hopkins All Children's in the 2024 Johns Hopkins Medicine Clinical Awards. Dr. Stapleton is on the Pediatric Palliative Care Team at Johns Hopkins All Children’s, and she specializes in symptom control and end of life care. She has been awarded numerous grants for phase I studies for patients with brain and spinal cord tumors as well as clinical research in pediatric palliative care. Dr. Stapleton’s research experience includes investigator-initiated and multi-center research projects. Dr. Stapleton is an associate professor of pediatrics at the University of South Florida and an assistant professor in the department of pediatrics at Johns Hopkins University. Dr. Stapleton completed her medical training at St. Louis University School of Medicine, residency training at Lackland Air Force Base in Texas and fellowship training at Baylor College of Medicine/Texas Children’s Hospital. Dr. Stapleton also served 13 years in the United States Air Force. Dr. Stapleton is a member of the American Board of Pediatrics, the Children’s Oncology Group, the Society of Neuro-Oncology, American Society of Pediatric Hematology/Oncology, and America Academy of Hospice and Palliative Medicine.

Dr. Stapleton is highly rated in 11 conditions, according to our data. Her top areas of expertise are Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, Histiocytosis, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 26 peer reviewed articles and participating in 22 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
San Antonio Uniformed Services, Pediatrics, 1999
Specialties
Pediatrics
Palliative Medicine
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in FL
Board Certifications
American Board Of Pediatrics
Fellowships
Baylor College of Medicine, Pediatric Hematology-Oncology, 2006
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
View 7 Less Insurance Carriers -

Locations

Johns Hopkins All Children's Outpatient Care, St. Petersburg
Suite 320, Saint Petersburg, FL 33701
Call: 727-767-4176
Other Locations
Johns Hopkins All Children's Outpatient Care, Tampa
12220 Bruce B Downs Boulevard, Tampa, FL 33612
Call: 727-767-4176

Additional Areas of Focus

Dr. Stapleton has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


22 Clinical Trials

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drug: Tipifarnib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Procedure, Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Procedure, Drug
Study Drugs: Larotrectinib, Larotrectinib Sulfate
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Other, Drug
Study Drug: Ulixertinib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Procedure, Other, Drug
Study Drug: Erdafitinib
Study Phase: Phase 2
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Intervention Type: Procedure, Radiation, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug
Study Drug: Ivosidenib
Study Phase: Phase 2
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Other, Drug
Study Drug: Ensartinib
Study Phase: Phase 2
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Enrollment Status: Active_not_recruiting
Publish Date: October 27, 2025
Intervention Type: Drug, Radiation, Biological, Other
Study Drugs: Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Vincristine
Study Phase: Phase 3
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Other, Procedure
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: Cisplatin, Cyclophosphamide, Lomustine, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drug: Mirdametinib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
Enrollment Status: Completed
Publish Date: February 05, 2025
Intervention Type: Drug, Other
Study Drugs: Selumetinib, Selumetinib Sulfate
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Procedure, Drug
Study Drug: Samotolisib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Drug: Vemurafenib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
Enrollment Status: Completed
Publish Date: November 01, 2024
Intervention Type: Other, Drug
Study Drug: Palbociclib
Study Phase: Phase 2
A Phase 2/3, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Response Comparison of the Efficacy and Safety of a Topical Rapamycin Cream for the Treatment of Facial Angiofibromas (FA) Associated With Tuberous Sclerosis Complex (TSC) in Patients 6 Years of Age and Over
A Phase 2/3, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Response Comparison of the Efficacy and Safety of a Topical Rapamycin Cream for the Treatment of Facial Angiofibromas (FA) Associated With Tuberous Sclerosis Complex (TSC) in Patients 6 Years of Age and Over
Enrollment Status: Completed
Publish Date: September 08, 2023
Intervention Type: Drug
Study Drug: Rapamycin
Study Phase: Phase 2/Phase 3
A Phase I Trial of Dose Escalation of Metformin in Combination With Vincristine, Irinotecan, and Temozolomide in Children With Relapsed or Refractory Solid Tumors
A Phase I Trial of Dose Escalation of Metformin in Combination With Vincristine, Irinotecan, and Temozolomide in Children With Relapsed or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: January 13, 2023
Intervention Type: Drug
Study Drugs: Vincristine, Irinotecan, Temozolomide, Metformin
Study Phase: Phase 1
View 21 Less Clinical Trials

26 Total Publications

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 08, 2024
View All 26 Publications
Similar Doctors
Expertise in
9
conditions
Dr. Damon R. Reed
Pediatric Hematology Oncology
Expertise in
9
conditions
Dr. Damon R. Reed
Pediatric Hematology Oncology
12902 Usf Magnolia Dr, Fob1 Sarcoma Program, 
Tampa, FL 
 (24.0 miles away)
813-745-3242
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Damon Reed is a Pediatric Hematologist Oncology provider in Tampa, Florida. Dr. Reed is highly rated in 9 conditions, according to our data. His top areas of expertise are Osteosarcoma, Ewing Sarcoma, Adult Soft Tissue Sarcoma, and Rhabdomyosarcoma.

Adrianna Vlachos
Expertise in
15
conditions
Dr. Adrianna Vlachos
Hematology | Pediatric Hematology Oncology
Expertise in
15
conditions
Dr. Adrianna Vlachos
Hematology | Pediatric Hematology Oncology

Johns Hopkins All Children's Outpatient Care, St. Petersburg

Saint Petersburg, FL 
 (0.1 miles away)
727-767-4176
Languages Spoken:
English, Greek
See accepted insurances
Offers Telehealth

Dr. Vlachos is the chief of hematology in the Johns Hopkins All Children’s Hospital Cancer & Blood Disorders Institute in St. Petersburg, Florida, and professor of pediatrics (PAR) in the Johns Hopkins University School of Medicine. She joined the hospital staff in 2024. She was previously professor of pediatrics at Zucker School of Medicine at Hofstra/Northwell and attending physician in hematology/oncology at Cohen Children’s Medical Center/Northwell Health, where she was head of the Bone Marrow Failure Program and head of the pediatric hematology/oncology trials office. Dr. Vlachos is internationally known for clinical care and expertise in bone marrow failure syndromes and her transformational research in Diamond Blackfan anemia (DBA) syndrome, a rare inherited bone marrow failure syndrome. Dr. Vlachos is the founder and has directed the Diamond Blackfan Anemia Registry (DBAR) of North America since its inception in 1991. She is the principal investigator and co-investigator on multiple grants funded by the National Institute of Health and the Centers for Disease Control and Prevention. She has published numerous articles on her research findings and has been invited to author papers and book chapters on bone marrow failure syndromes and DBA. Dr. Vlachos is a member of the Medical and Scientific Advisory Board for the Shwachman-Diamond Syndrome Registry, is a member of the Scientific Advisory Board for the Diamond Blackfan Anemia Foundation and holds a position on the Scientific Program Committee for Bone Marrow Failure of the American Society of Hematology. She earned her medical degree from New York Medical College in Valhalla, New York. She completed her residency in pediatrics at North Shore University Hospital in Manhasset, New York. She then completed a clinical fellowship in bone marrow transplantation at North Shore University Hospital, followed by a fellowship in pediatric hematology-oncology and bone marrow transplantation at Mount Sinai Medical Center in New York. Videos Bone Marrow Failure Syndrome Expert Dr. Adrianna Vlachos at Johns Hopkins All Children’s. Dr. Vlachos is highly rated in 15 conditions, according to our data. Her top areas of expertise are Aase Syndrome, Pure Red Cell Aplasia, Aplastic Anemia, and Transient Erythroblastopenia of Childhood.

Jonathan Metts
Expertise in
6
conditions
Dr. Jonathan Metts
Pediatric Hematology Oncology
Expertise in
6
conditions
Dr. Jonathan Metts
Pediatric Hematology Oncology

Johns Hopkins All Children's Outpatient Care, St. Petersburg

601 5th Street South, Suite 320, Suite 320, 
Saint Petersburg, FL 
 (0.1 miles away)
727-767-4176
Languages Spoken:
English
See accepted insurances

Dr. Metts specializes in pediatric hematology/oncology in the Johns Hopkins All Children's Cancer & Blood Disorders Institute. He sees patients on our main campus in St. Petersburg and at the Johns Hopkins All Children’s Outpatient Care Center in Tampa. He joined the hospital in 2016. He received his medical degree from the University of South Carolina School of Medicine and completed an internship and residency in pediatrics at Johns Hopkins All Children’s Hospital through the University of South Florida Morsani School of Medicine. Dr. Metts then trained at Emory University School of Medicine as a pediatric hematology/oncology fellow. His clinical interests include sarcomas, rare solid tumors, and Phase 1 and Phase 2 trials for pediatric solid tumors. Dr. Metts is highly rated in 6 conditions, according to our data. His top areas of expertise are Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, and Adult Soft Tissue Sarcoma.

VIEW MORE Pediatricians

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stapleton's expertise for a condition
ConditionClose
    • Distinguished
    • Medulloblastoma
      Dr. Stapleton is
      Distinguished
      . Learn about Medulloblastoma.
      See more Medulloblastoma experts
    • Advanced
    • Denys-Drash Syndrome (DDS)
      Dr. Stapleton is
      Advanced
      . Learn about Denys-Drash Syndrome (DDS).
      See more Denys-Drash Syndrome (DDS) experts
    • Embryonal Tumor with Multilayered Rosettes
      Dr. Stapleton is
      Advanced
      . Learn about Embryonal Tumor with Multilayered Rosettes.
      See more Embryonal Tumor with Multilayered Rosettes experts
    • Ewing Sarcoma
      Dr. Stapleton is
      Advanced
      . Learn about Ewing Sarcoma.
      See more Ewing Sarcoma experts
    • Glioma
      Dr. Stapleton is
      Advanced
      . Learn about Glioma.
      See more Glioma experts
    • Hepatoblastoma
      Dr. Stapleton is
      Advanced
      . Learn about Hepatoblastoma.
      See more Hepatoblastoma experts
    • Histiocytosis
      Dr. Stapleton is
      Advanced
      . Learn about Histiocytosis.
      See more Histiocytosis experts
    View All 10 Advanced Conditions
    • Experienced
    • Adult Soft Tissue Sarcoma
      Dr. Stapleton is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Bone Marrow Aspiration
      Dr. Stapleton is
      Experienced
      . Learn about Bone Marrow Aspiration.
      See more Bone Marrow Aspiration experts
    • Neuroblastoma
      Dr. Stapleton is
      Experienced
      . Learn about Neuroblastoma.
      See more Neuroblastoma experts
    • Neurofibromatosis
      Dr. Stapleton is
      Experienced
      . Learn about Neurofibromatosis.
      See more Neurofibromatosis experts
    • Neurofibromatosis Type 1 (NF1)
      Dr. Stapleton is
      Experienced
      . Learn about Neurofibromatosis Type 1 (NF1).
      See more Neurofibromatosis Type 1 (NF1) experts
    • Osteosarcoma
      Dr. Stapleton is
      Experienced
      . Learn about Osteosarcoma.
      See more Osteosarcoma experts
    View All 10 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    1. Homepage
    2. Pediatricians Saint Petersburg, FL
    3. Dr. Stacie L. Stapleton
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment